Form 4: REVB Director Sells Shares for Tax Obligations

Revelation Biosciences Director Lakhmir S Chawla sold 2,261 shares of common stock to cover tax obligations following a restricted stock award vesting.

Summary

• Revelation Biosciences, Inc. Director Lakhmir S Chawla disposed of 2,261 shares of common stock.
• The transaction occurred on February 3, 2026, at a weighted average price of $1.85 per share, with prices ranging from $1.84 to $1.87.
• The sale was mandatory and executed by the issuer on behalf of Mr. Chawla solely to satisfy tax withholding obligations arising from the vesting of restricted stock awards.
• Following this transaction, Mr. Chawla beneficially owns 12,158 shares of common stock.
• All share numbers reported reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it reduces insider ownership, it's a routine, mandatory transaction for tax purposes following restricted stock vesting, not an discretionary sale.

Positives

• The underlying event is the vesting of restricted stock awards, which indicates compensation for the director.

Negatives

• A reduction in direct beneficial ownership by a director, even if for tax purposes, slightly decreases insider alignment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that sales of shares to cover tax obligations upon the vesting of restricted stock awards are a common and routine practice for executives and directors across various industries. This type of transaction is typically not indicative of a change in management's sentiment towards the company's future prospects but rather a standard compensation and tax management procedure.

Comparison to Industry Standards

• The practice of selling shares to cover tax withholding upon restricted stock vesting is a standard compensation and tax management mechanism widely adopted by public companies, including those in the biotechnology sector like Revelation Biosciences.
• This type of transaction is comparable to similar tax-related sales observed at companies such as Pfizer, Moderna, or Johnson & Johnson, where executives often sell a portion of their vested equity awards to meet statutory tax requirements.
• The transaction price range of $1.84 to $1.87 is specific to REVB's stock performance around the transaction date and is not directly comparable to other companies' stock prices without further context.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary sale for tax purposes, not signaling a change in director confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a director to cover tax obligations upon the vesting of restricted stock awards. Such transactions are common and do not typically reflect a change in the director's outlook on the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Revelation Biosciences, REVB, Lakhmir S Chawla, Form 4, Insider Trading, Stock Sale, Tax Obligations, Restricted Stock, Reverse Stock Split, Director Transaction